Search Site

Trends banner

‘Wadeem’ sold out for $1.49bn

This is the highest Abu Dhabi real-estate release to date.

Tesla Q2 sales down 13.5%

Shares rally after the disclosure, better than some forecasts.

TomTom cuts 300 jobs

The firm said it was realigning its organization as it embraces AI.

Aldar nets $953m in sales at Fahid

Aldar said 42 percent of the buyers are under the age of 45.

Qualcomm to Alphawave for $2.4 bn

The deal makes Alphawave the latest tech company to depart London.

Vaccine factory to come up in Khazaen City with $52m outlay

The rise in producer price index was driven by a hike in oil and gas prices.
  • The agreement was signed by Khazaen CEO Salim Al Thuhli and Opal’s Chairman of the Board of Directors, Sa’ad Moosa Al Junaibi
  • Al Thuhli was quoted by the official sources as saying that the project would be the first vaccine factory in Khazaen Economic City

The Khazaen Economic City in Oman has signed an agreement with biopharmaceuticals business company Opal to establish a factory for the production of biological human vaccines, official sources have said.

The deal was signed in Muscat on Wednesday, and has an outlay of OMR20 million (around $52 million), said the sources.

The first phase of the project is expected to be set up on a total area of 37,000 square meters.

The agreement was signed by Khazaen CEO Salim Al Thuhli and Opal’s Chairman of the Board of Directors, Sa’ad Moosa Al Junaibi.

Al Thuhli was quoted by the official sources as saying that the project would be the first vaccine factory in Khazaen Economic City.

He added that it targets local and international markets.

The agreement, Al Thuhli added, comes as part of Khazaen’s efforts in attracting local and international investments.